Yeshi Neumann, C.N.M. Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 195 Sunset Way, Muir Beach, CA 94965 Phone: 415-407-6576 |
News Archive
Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(®) Biliary RX fully and partially covered stents for the palliative treatment of malignant bile duct strictures. The WallFlex Biliary RX uncovered stent was cleared by the FDA in 2006.
In patients with metastatic renal cell carcinoma, the biomarker serum lactate dehydrogenase is both prognostic for survival and predictive for the survival benefit conferred by the TORC1 inhibitor temsirolimus, research shows.
The net clinical benefit of anticoagulants for atrial fibrillation (AF) - one of the most important causes of irregular heartbeats and a leading cause of stroke - decreases with age, as the risk of death from other factors diminishes their benefit in older patients, according to a study led by researchers at UC San Francisco.
Catalyst Health Solutions, Inc. today announced that it plans to sell 5,500,000 shares of its common stock, subject to market and other conditions, of which 4,500,000 shares will be sold by the Company and 1,000,000 shares will be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., in an underwritten public offering pursuant to an automatic shelf registration statement on Form S-3 filed today with the Securities and Exchange Commission.
› Verified 7 days ago